Telehealth Peptides
Clinician-supervised peptide therapy delivered through a US telemedicine platform. This page explains what makes compounded peptide therapy legal under Section 503A of the Federal Food, Drug, and Cosmetic Act, what “safe”actually means as a process attribute in clinician-supervised peptide care, and how telemedicine peptide service is structured at TelePeptide.
Legal Framework
Are peptides legal in the United States?
Yes — when prescribed by a licensed clinician and dispensed by a licensed compounding pharmacy. Peptide therapy operates under three converging legal frameworks: (1) the Federal Food, Drug, and Cosmetic Act's Section 503A, which authorizes patient-specific compounding by state-licensed pharmacies; (2) state pharmacy law, which licenses and inspects compounding pharmacies; and (3) state telehealth practice acts, which govern the prescriber-patient relationship required before any prescription may be written.
What is notlegal: buying peptides from a website that disclaims therapeutic use, sells “research only” vials with no prescription requirement, ships from unregulated facilities, and offers no clinician oversight. That category exists in a different regulatory space than the prescription-pharmacy compounding category. The two look superficially similar to a consumer scrolling search results, but they are different categories of law.
TelePeptide operates exclusively in the prescription-pharmacy compounding category. Every preparation dispensed for a TelePeptide patient is (a) prescribed by a clinician licensed in that patient's state, (b) prepared by a LegitScript-certified Section 503A compounding pharmacy operating under state board of pharmacy licensure, and (c) dispensed to a specific named patient — not a research subject, not a wholesale buyer.
Compounded peptide preparations are not FDA-approved finished drug products. That is a regulatory category distinction, not a safety or legality claim. FDA approval applies to mass-manufactured branded drugs; Section 503A compounding occupies a separate regulatory channel designed for patient-specific preparations.
For deeper regulatory detail, see 503A vs 503B compounding pharmacies and the 503A bulk drug substances list explained.
Safety as a Process Attribute
Are peptides safe?
“Safe” is not a property of the molecule alone. It is a property of the process around the molecule. In peptide therapy, “safe” depends on three process attributes:
1. Clinician supervision
Every prescription is written by a licensed clinician after an individualized medical evaluation. Lab work is ordered where clinically indicated. Follow-up consultations are scheduled at appropriate intervals. Dose titration is clinician-determined based on response, side effects, and lab markers — not patient-determined or internet-protocol-determined. Telemedicine does not reduce the clinical standard. A telehealth peptide service that does not involve real clinician evaluation, real prescriptions, real labs, and real follow-up is operating outside the clinician-supervised category.
2. Pharmacy quality
Compounded peptide preparations should be dispensed by Section 503A pharmacies operating under state board of pharmacy licensure, USP <797> sterile-compounding standards (for injectables), USP <795> for non-sterile preparations, and routine state inspections. LegitScript certification is an additional independent verification layer. TelePeptide's five pharmacy partners (Strive, Empower, Medivera, Epiq Scripts, and Emerald Compounding) are each LegitScript-certified.
3. Honest contraindication screening
Peptide therapy is not appropriate for every patient. Licensed clinicians screen for absolute contraindications (active malignancy, pregnancy/lactation, pediatric epiphyseal closure not yet complete, others depending on the molecule) and for relative contraindications that require additional monitoring. A platform that prescribes the same medication to everyone who fills an intake form, without individualized clinical judgment, is not delivering safe peptide care regardless of which molecule it sells.
Compounded preparations are not FDA-approved finished drug products. Individual response varies. This page is educational and is not medical advice. Whether peptide therapy is clinically appropriate for any individual is determined by a licensed clinician.
For the honest side-effect profile across compounded peptide preparations, see Are peptides safe? — an honest 2026 assessment and peptide therapy contraindications.
Telemedicine Peptide Care
How telehealth peptide therapy works
Telehealth peptide therapy is the delivery of clinician-supervised compounded peptide care through a telemedicine platform rather than an in-person clinic visit. The clinical elements are the same as in-person care: history and physical, evaluation, labs where indicated, prescription, monitoring, follow-up. The delivery channel is different.
The TelePeptide workflow
- Intake. Patient completes a structured intake form at telepeptide.org/intake including medical history, current medications, allergies, and treatment goals. Government photo ID and a current selfie are uploaded for identity verification.
- Clinical evaluation. A licensed clinician contracted via MD Integrations, P.C. reviews the intake. For new prescriber-patient relationships, a synchronous video consultation is scheduled where state law requires it. Established patients may receive asynchronous store-and-forward review for refills and protocol-driven dose adjustments where clinically appropriate.
- Lab ordering. Where clinically indicated (e.g., HbA1c, lipid panel, IGF-1, CBC), labs are ordered through US-licensed laboratories.
- Prescription.The clinician writes a patient-specific electronic prescription transmitted to one of TelePeptide's five LegitScript-certified Section 503A pharmacy partners.
- Dispensing & shipping.The pharmacy compounds the preparation under USP <797> (sterile) or USP <795> (non-sterile) standards and ships directly to the patient via temperature-controlled overnight delivery. TelePeptide never takes possession of medications.
- Follow-up. Patients have HIPAA-compliant messaging with their assigned prescriber through the patient portal at telepeptide.org/portal (multi-factor-authentication protected). Lab follow-up at week 6, week 12, and every 6 months thereafter as clinically indicated.
- Adverse event reporting. A dedicated adverse-event reporting page at telepeptide.org/report-side-effects provides 24-hour clinical-acknowledgment for any reported side effect. Reportable events are forwarded to FDA MedWatch per 21 CFR 314.80 where required.
Service area
TelePeptide is available in 48 US states + the District of Columbia. Alaska and Mississippi are not served at this time. The intake form's state-of-residence dropdown excludes both. New Jersey-based operations are registered with the New Jersey Department of Health Telemedicine and Telehealth Organization Registry under N.J.S.A. 26:2H-12.16.
Medical group
Clinical services are provided by MD Integrations, P.C. — mdintegrations.com — a contracted medical group operating a multi-state network of licensed physicians, NPs, and PAs. TelePeptide LLC does not employ prescribers directly and does not engage in the practice of medicine.
Compliance Posture
What TelePeptide will and will not do
WILL
- · Compounded GLP-1 receptor agonists (semaglutide, tirzepatide)
- · Sermorelin (GHRH analog) under endocrine evaluation
- · NAD+ precursor therapy
- · Hormone optimization (estradiol, enclomiphene) where indicated
- · B-vitamin / nutrient preparations (B12, MIC, glutathione)
- · Synchronous video and asynchronous review per state law
- · Lab-driven titration with documented follow-up
- · FDA MedWatch adverse-event reporting per 21 CFR 314.80
WILL NOT
- · FDA Schedule I–V controlled substances
- · Opioids, stimulants, benzodiazepines
- · Abortifacient products (mifepristone, misoprostol)
- · Medical-marijuana cards or cannabinoid products
- · FDA-unapproved investigational peptides
- · Pediatric care
- · Acute, urgent, or emergency care (call 911 for emergencies)
- · Branded FDA-approved finished drug products
Start your clinical evaluation
Every TelePeptide prescription begins with an individualized clinical evaluation by a licensed clinician. Whether compounded peptide therapy is clinically appropriate for you is determined by the prescriber based on your medical history, current medications, and lab work where indicated.
Begin Intake →Compounded by licensed 503A pharmacies. Not FDA-approved as finished drug products. Clinical services provided by MD Integrations, P.C. — a contracted medical group operating a multi-state network of licensed physicians, NPs, and PAs. Available in 48 US states + DC (excludes AK and MS). Not medical advice. Individual response varies.